达格列净对不同BMI的初发2型糖尿病人群体质量、血脂、血糖的影响  

Effects of Dapagliflozin on Body Weight,Blood Lipids and Blood Glucose in Newly-onset Type 2 Diabetes Mellitus with Different BMI

作　　者：周蒙蒙 ZHOU Mengmeng(Department of Endocrinology,People's Hospital of Ningjin County,Ningjin,Shandong Province,253400 China)

机构地区：[1]宁津县人民医院内分泌科,山东宁津253400

出　　处：《糖尿病新世界》2022年第5期75-79,共5页Diabetes New World Magazine

摘　　要：目的观察达格列净对不同体质指数(BMI)的初发2型糖尿病患者的降糖、降脂、减重效果。方法回顾分析2019年6月—2021年1月宁津县人民医院收治的不同BMI的初诊2型糖尿病患者60例,按体质量分为超重组和肥胖组,每组30例。超重组BMI为24~28 kg/m^(2),肥胖组BMI为>28 kg/m^(2),每组患者均给予相同的降糖方案,分别记录治疗开始和治疗3个月后BMI、腰臀比、空腹血糖、餐后2 h血糖、HbA1c、血脂指标。结果超重组及肥胖组均有28例完成观察。治疗前,肥胖组体质量、体质指数、腰臀比、三酰甘油均高于超重组,差异有统计学意义(P<0.05)。治疗后,两组空腹血糖、餐后2 h血糖、HbA1c、血脂、BMI、血尿酸等指标均较治疗前有所下降,差异有统计学意义(P<0.05)。治疗后,超重组空腹血糖、HbA1c较肥胖组下降更明显,差异有统计学意义(P<0.05)。超重组治疗前后体质量下降数值较肥胖组明显,差异有统计学意义(P<0.05)。结论达格列净对初诊的超重2型糖尿病患者降低体质量,降糖效果优于肥胖患者。Objective To observe the effect of dapagliflozin on hypoglycemic,lipid-lowering and weight loss in newly diagnosed type 2 diabetic patients with different BMI.Methods A retrospective analysis of 60 newly diagnosed type 2 diabetes patients with different BMI admitted to Ningjin County People's Hospital from June 2019 to January 2021 was divided into overweight and obesity groups according to body weight,with 30 cases in each group.The BMI of the overweight group was 24-28 kg/m^(2),and the BMI of the obese group was>28 kg/m^(2).The patients in each group were given the same hypoglycemic regimen,and the BMI,waist-to-hip ratio,and fasting blood glucose,2 h postprandial blood glucose,HbA1c,blood lipid indexes were recorded at the beginning of treatment and after 3 months of treatment.Results 28 cases in the overweight and obese groups completed the observation.Before treatment,the body weight,body mass index,waist-to-hip ratio and triglyceride in the obese group were higher than those in the overweight group,and the difference was statistically significant(P<0.05).After treatment,fasting blood glucose,2 h postprandial blood glucose,HbA1c,blood lipids,BMI,blood uric acid and other indicators in the two groups were decreased compared with those before treatment,and the difference was statistically significant(P<0.05).After treatment,the overweight fasting blood glucose and HbA1c decreased more significantly than those in the obese group,and the difference was statistically significant(P<0.05).The weight loss before and after overweight treatment was significantly higher than that in the obese group,and the difference was statistically significant(P<0.05).Conclusion Dapagliflozin is better than obese patients in reducing body weight and blood glucose in newly diagnosed overweight patients with type 2 diabetes.

关 键 词：2型糖尿病 达格列净 BMI 血糖 HBA1C 

分 类 号：R587.1[医药卫生—内分泌]